Ipsen Innovation
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$13.6M
Doctors Paid
188
Transactions
6,490
2024 Total
$5.8M
Payment Breakdown by Category
Research$11.7M (86.2%)
Consulting$1.0M (7.5%)
Travel$411,897 (3.0%)
Food & Beverage$62,832 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $11.7M | 5,628 | 86.2% |
| Consulting Fee | $1.0M | 220 | 7.5% |
| Travel and Lodging | $411,897 | 287 | 3.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $248,844 | 42 | 1.8% |
| Compensation for serving as faculty or as a speaker for a medical education program | $89,719 | 26 | 0.7% |
| Food and Beverage | $62,832 | 282 | 0.5% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $44,522 | 5 | 0.3% |
Payments by Type
Research
$11.7M
5,628 transactions
General
$1.9M
862 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Multiple-dose, Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dysport for the Treatment of Pain Associated With Hallux Abducto Valgus | $2.3M | 3 | 308 |
| Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | $2.2M | 3 | 2,236 |
| A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | $1.9M | 2 | 1,931 |
| A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis | $1.7M | 0 | 516 |
| A Phase 2 Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva in Male and Female Paediatric and Adult Participants. | $1.4M | 8 | 274 |
| A Phase III, Multicentre, Double Blind, Prospective, Randomised, Controlled, Multiple Treatment Study Assessing Efficacy And Safety Of DYSPORT Used In The Treatment Of Upper Limb Spasticity In Children | $1.4M | 0 | 140 |
| A Phase II, Multicentre, Double-blind, Randomised, Placebo Controlled, Dose Escalation and Dose Finding Study to Evaluate the Efficacy and Safety of Dysport in Vulvodynia Patients | $464,881 | 1 | 139 |
| Dysport Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity NDO Due to Spinal Cord Injury or Multiple Sclerosis - Study 1 CONTENT1 | $59,196 | 0 | 10 |
| A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | $53,584 | 0 | 47 |
| ArmA | $44,669 | 0 | 3 |
| A Phase II, Randomized, Open-label Study to Assess the Efficacy, Safety, and Pharmacokinetics (PK) of Maintenance Cabozantinib (XL184) Plus Best Supportive Care (BSC) Versus BSC in Children, Adolescents and Young Adults (AYA) With Unresectable Residual Osteosarcoma Either at Diagnosis or at First Relapse After Standard Treatment | $22,670 | 1 | 8 |
| Validation of Patient Reported Outcome Measures for Use in Vulvodynia | $11,750 | 0 | 2 |
| A Phase III, Multicentre,Double Blind, Prospective, Randomised, Controlled, Multiple Treatment Study Assessing Efficacy And Safety OfDYSPORTUsed In The Treatment Of Upper Limb Spasticity In Children | $11,222 | 0 | 4 |
| Validation of the modified Foot Function Index mFFI for Use in Hallux Valgus | $8,915 | 0 | 2 |
| Validation of the Modified Foot Function IndexmFFI for Use in Hallux Valgus | $4,995 | 0 | 4 |
| International Multicentre Validation Study ofSAGIT Instrument in Acromegaly | $1,256 | 1 | 1 |
| A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport For The Treatment Of UrinaryIncontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis | $225.00 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Kris Kowdley, Md, MD | Gastroenterology | Seattle, WA | $22,269 | $0 |
| Eric Jonasch, M.d, M.D | Medical Oncology | Houston, TX | $20,610 | $0 |
| Prof. David Armstrong, Dpm, Phd, DPM, PHD | Podiatrist | Los Angeles, CA | $20,422 | $0 |
| Ghassan Abou-Alfa, Md, MD | Medical Oncology | New York, NY | $19,967 | $0 |
| Richard Zorowitz, M.d, M.D | Physical Medicine & Rehabilitation | Washington, DC | $18,995 | $0 |
| Ramtin Kassir, M.d, M.D | Otolaryngology | Wayne, NJ | $18,764 | $0 |
| Dr. Cynthia Levy, Md, MD | Gastroenterology | Miami, FL | $17,775 | $0 |
| Dr. Cynthia Comella, Md, MD | Neurology | Chicago, IL | $17,393 | $0 |
| Dr. Sumanta Pal, Md, MD | Internal Medicine | Duarte, CA | $17,347 | $0 |
| Dr. Allen Jacobs, Dpm, DPM | Foot & Ankle Surgery | Saint Louis, MO | $17,243 | $0 |
| Dr. David Dodick, M.d, M.D | Neurology | New York, NY | $17,125 | $0 |
| Hyder Jinnah, Md Phd, MD PHD | Neurology | Atlanta, GA | $16,956 | $0 |
| Allison Brashear, Md, MD | Neurology | Sacramento, CA | $15,304 | $0 |
| Hanny Al-Samkari, Md, MD | Hematology & Oncology | Boston, MA | $15,225 | $0 |
| Dr. Stephen Silberstein, M.d, M.D | Neurology | Philadelphia, PA | $15,004 | $0 |
| Brett Kissela, Md, MD | Neurology | Cincinnati, OH | $14,732 | $0 |
| Bahman Jabbari, Md, MD | Neurology | New Haven, CT | $14,507 | $0 |
| Peter Goadsby, Md, MD | Internal Medicine | Los Agneles, CA | $14,413 | $0 |
| Jason Reichenberg, M.d, M.D | Dermatology | Austin, TX | $14,148 | $0 |
| Dr. Virginia Kimonis, Md, MD | Clinical Genetics (M.D.) | Orange, CA | $14,068 | $0 |
| Justin Harper, M.d, M.D | Medical Specialty | Columbus, OH | $12,898 | $0 |
| Christopher Surek, D.o, D.O | Student in an Organized Health Care Education/Training Program | Cleveland, OH | $12,325 | $0 |
| Dr. Todd Schwedt, Md, MD | Neurology | Phoenix, AZ | $12,271 | $0 |
| Karen Klein, M.d, M.D | Pediatric Endocrinology | San Diego, CA | $12,198 | $0 |
| Nizar Tannir, M.d, M.D | Medical Oncology | Houston, TX | $11,838 | $0 |
Ad
Top Products
- Dysport $6.4M
- DYSPORT $3.5M
Associated Products (4)
- Dysport $16.6M
- DYSPORT $8.5M
- Dysport 300 U-1 $2.8M
- Somatuline $12,137
Payment Categories
- Food & Beverage $62,832
- Consulting $1.0M
- Travel & Lodging $411,897
- Research $11.7M
About Ipsen Innovation
Ipsen Innovation has made $13.6M in payments to 188 healthcare providers, recorded across 6,490 transactions in the CMS Open Payments database. In 2024, the company paid $5.8M. The top product by payment volume is Dysport ($6.4M).
Payments were distributed across 51 medical specialties. The top specialty by payment amount is Neurology ($523,380 to 42 doctors).
Payment categories include: Food & Beverage ($62,832), Consulting ($1.0M), Research ($11.7M), Travel & Lodging ($411,897).
Ipsen Innovation is associated with 4 products in the CMS Open Payments database, including Dysport, DYSPORT, and Dysport 300 U-1.